Long-Acting Therapeutic Could Take Place of HIV Vaccine
Induction of pathogen-specific immune responses is a principle of most, if not all, vaccines. This approach has so far proved unsuccessful for the development of an HIV vaccine. The report by Gardner et al. from Michael Farzan’s group at the Scripps Research Institute in Florida seems to find a solution by employing a new approach that uses genes encoding for a molecule of CD4 and CCR5mim1. This recombinant molecule binds to the HIV-1 envelope glycoprotein (Env) cooperatively and with higher avidity, therefore inhibiting virus binding to CD4+ T cells and preventing infection. Rhesus macaques inoculated with the vector (AAV) expressing this molecule showed full protection against multiple SHIV challenges. This protection can last for at least 34 weeks in the experimental macaques. This finding provides a hope for the development of an HIV preventive vaccine.
To support your research needs for customized DNA constructs for vaccine research, therapeutic antibody engineering, and immunology, General Biosystems offers Gene Synthesis services to provide the custom DNA constructs you need with 100% sequence accuracy.
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. To find out more about the cookies we use, see our Privacy Policy .
